Rampart Bioscience develops non-viral DNA delivery systems to provide durable gene therapies for genetically driven diseases. Their approach aims to enhance treatment efficacy and safety, addressing the need for long-lasting solutions in the management of inherited metabolic disorders and other genetic conditions.
Funding
$125M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
FCFounders
Product
Problem
Current gene therapies often struggle with efficacy and safety due to limitations in delivery methods, particularly the use of viral vectors, which can trigger immune responses and have limited durability. This creates a need for gene therapies that can provide long-lasting therapeutic effects without the risks associated with viral delivery.
Solution
Rampart Bioscience is developing non-viral DNA delivery systems to overcome the limitations of existing gene therapies. Their technology aims to provide durable therapeutic expression for genetically driven diseases by integrating advancements in gene delivery, protein sciences, and clinical translation. Rampart's approach focuses on creating optimized therapeutics in a redosable, non-viral format, addressing the need for safer and more effective gene medicines.
Target Audience
The primary target audience includes patients with genetically driven diseases, as well as researchers and clinicians seeking safer and more effective gene therapy solutions.
Features
- Proprietary non-viral DNA delivery platform for enhanced safety and redosability
- Versatile approach applicable to a wide range of genetic diseases
- Focus on achieving higher standards for potency and durability of gene therapies
- Development of a new mechanism for treating inherited metabolic disorders